Loading...
XNAS
TTNP
Market cap4mUSD
Nov 03, Last price  
3.48USD
Name

Titan Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:TTNP chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
31.73%
Rev. gr., 5y
-50.04%
Revenues
0k
-100.00%
89,00032,00024,00070,00079,00010,093,0004,068,0007,117,00010,481,0003,646,0001,671,00015,065,000215,0005,911,0003,611,0004,838,0001,526,00060,000184,0000
Net income
-5m
L-15.50%
-22,462,000-15,737,000-17,647,000-25,430,000-5,886,000-6,834,000-15,203,000-15,180,0009,711,000-2,403,000-11,279,0005,135,000-14,307,000-9,023,000-16,089,000-20,728,000-8,114,000-10,177,000-5,569,000-4,706,000
CFO
-4m
L-45.29%
-22,921,000-13,500,000-15,188,000-25,340,000-5,407,000-4,657,000-14,476,0001,830,000-9,799,000-5,865,000-7,466,0006,293,000-13,038,000-8,431,000-15,445,000-17,203,000-7,899,000-8,183,000-7,092,000-3,880,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
URL
https://www.titanpharm.com/
IPO date
Jan 18, 1996
Employees
4
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT